FDA Sets Date for Decision on Shire ADHD Drug
Posted on: Monday, 13 March 2006, 12:00 CST
After accepting the resubmission of the new drug application for Shire's ADHD drug, Daytrana, the FDA has said that it will complete its review of the drug by April 9, 2006.
Shire resubmitted its application for the drug to the FDA with additional data after the regulator informed the company in December 2005 via an approvable letter that it would need more information before it could approve the drug. The FDA now has 60 days to complete its review of the resubmission.
The concerns that the FDA raised in its approvable letter for the drug centered on proposed revisions to labeling, as well as requests for data clarification, post-marketing surveillance, and post-marketing studies.
Daytrana, licensed globally from Noven Pharmaceuticals, is a developmental product for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 to 12 years.
If Daytrana is ultimately approved, Noven would be entitled to receive a $50 million milestone payment from Shire, and would have the opportunity to earn additional milestone payments of up to $75 million depending on the level of Shire's commercial sales of the product. In addition, Noven expects to earn a profit on the manufacture and supply of finished product to Shire.
Source: Datamonitor
Related Articles
- XDx's AlloMap(R) Gene Expression Test Cleared By U.S. Food and Drug Administration (FDA)
- Commenting on the U.S. Food and Drug Administration (FDA) Early Communication, Allergan Clarifies FDA's Inquiry Relates Primarily to High Dose Medical Uses of BOTOX(R), Rather Than BOTOX(R) Cosmetic for Aesthetic Use
- TyRx Pharma, Inc. Announces Food and Drug Administration (FDA) 510(K) Clearance of the AIGIS(Rx)(TM) Cardiac Rhythm Medical Device (CRMD) Anti-Bacterial Envelope, an Innovative Mesh Envelope Designed to Immobilize and Reduce Bacterial Infection of a Pacem
- TYZEKA(TM) (Telbivudine) Approved By U.S. Food and Drug Administration (FDA) As a New Treatment for Patients With Chronic Hepatitis B
- Chemical Heritage Foundation (CHF) and the Food and Drug Administration (FDA) Will Cosponsor FDA Centennial Conference at CHF on Tuesday, 16 May 2006
- FDA Approves POSILAC(R) Production at Monsanto's Augusta Facility
- FDA Approves Halozyme Product: Hylenex Will Aid Absorption of Drugs
- Shire and Noven Resubmitted NDA for MTS, a Candidate Treatment for Pediatric ADHD Patients
- Shire and Noven Announce Positive Clinical Data for Transdermal ADHD Treatment
- U.S. Food and Drug Administration (FDA) Approves BARACLUDE(TM) (Entecavir) for Treatment of Chronic Hepatitis B
 |
 |
User Comments (0)
RSS Feeds